Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
lurbinectedin
real-world data
real-world evidence
small cell lung cancer
survival outcomes
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
18 Feb 2024
18 Feb 2024
Historique:
received:
07
05
2023
accepted:
24
01
2024
medline:
19
2
2024
pubmed:
19
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum-containing therapy. Multicentre real-world study of individuals with SCLC initiating lurbinectedin monotherapy (3.2 mg/m Data were analysed for 46 individuals across seven sites. Lurbinectedin was given as second- (83%, 38/46) or subsequent- (17%, 8/46) line therapy, mostly with prior chemoimmunotherapy (87%, 40/46). We report dose modifications (17%, 8/46), interruptions/delays (24%, 11/46), high-grade toxicities (28%, 13/46) and hospitalisations (54%, 25/46) during active treatment. The overall response rate was 33% and the disease control rate was 50%. Six-month OS was 44% (95% confidence interval (CI): 29.0-57.1). Twelve-month OS was 15% (95% CI: 6.5-26.8). From lurbinectedin first dose, the median PFS was 2.5 months (95% CI: 1.8-2.9) and OS was 4.5 months (95% CI: 3.5-7.2). From SCLC diagnosis, the median OS was 12.9 months (95% CI: 11.0-17.2). Individuals with a longer chemotherapy-free interval prior to lurbinectedin had longer PFS and OS. This real-world national experience of lurbinectedin post-platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum-containing therapy.
METHODS
METHODS
Multicentre real-world study of individuals with SCLC initiating lurbinectedin monotherapy (3.2 mg/m
RESULTS
RESULTS
Data were analysed for 46 individuals across seven sites. Lurbinectedin was given as second- (83%, 38/46) or subsequent- (17%, 8/46) line therapy, mostly with prior chemoimmunotherapy (87%, 40/46). We report dose modifications (17%, 8/46), interruptions/delays (24%, 11/46), high-grade toxicities (28%, 13/46) and hospitalisations (54%, 25/46) during active treatment. The overall response rate was 33% and the disease control rate was 50%. Six-month OS was 44% (95% confidence interval (CI): 29.0-57.1). Twelve-month OS was 15% (95% CI: 6.5-26.8). From lurbinectedin first dose, the median PFS was 2.5 months (95% CI: 1.8-2.9) and OS was 4.5 months (95% CI: 3.5-7.2). From SCLC diagnosis, the median OS was 12.9 months (95% CI: 11.0-17.2). Individuals with a longer chemotherapy-free interval prior to lurbinectedin had longer PFS and OS.
CONCLUSION
CONCLUSIONS
This real-world national experience of lurbinectedin post-platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Specialised Therapeutics
Informations de copyright
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2018, Based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
Sabesan S, Zalcberg J, Underhill C, Zielinski R, Burbury K, Ansari Z et al. Implementation of the Australasian Teletrial Model: lessons from practice. Asia Pac J Clin Oncol 2019; 15: 3-14.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19: 1441-1464.
O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447.
Chen L, Antras L, Duh MS, Neary M, O'Brien ME. Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. J Thorac Oncol 2008; 3: 1137-1145.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020; 21: 645-654.
Besse B, Paz-Ares LG, Peters S, Cappuzzo F, Reck M, Calles A et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). J Clin Oncol 2023; 41: TPS8613.
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMfort). NCT05091567. ClinicalTrials.gov. Available from URL: https://clinicaltrials.gov/study/NCT05091567#publications.
Steffens CC, Elender C, Hutzschenreuter U, Dille S, Binninger A, Spring L et al. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - results from the prospective German TLK cohort study. Lung Cancer 2019; 130: 216-225.
Tendler S, Zhan Y, Pettersson A, Lewensohn R, Viktorsson K, Fang F et al. Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study. Acta Oncol 2020; 59: 388-394.
Huang J, Faisal W, Brand M, Smith S, Alexander M, Conron M et al. EP14.05-016 patterns of care for small cell lung cancer in Victoria Australia. A prospective population-based observational study. J Thorac Oncol 2022; 17: 550.
Rittberg R, Leung B, Al-Hashami Z, Ho C. Real world patient eligibility for second line lurbinectedin based treatment in small cell lung cancer: understanding epidemiology and estimating health care utilization. Curr Oncol 2022; 29: 9744-9752.
Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB et al. Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set. JCO Clin Cancer Inform 2019; 3: 1-13.
Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF et al. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med 2023; 11: 74-86.
Paz-Ares L, Ciuleanu T, Navarro A, Fulop A, Cousin S, Bonanno L et al. PL02.03 Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: phase III randomized ATLANTIS trial. J Thorac Oncol 2021; 16: S844-S845.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
Toublanc AC, Guecamburu M, Veillon R, Rosellini P, Girodet PO, Zysman M. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: preliminary results in real-clinical practice. Thorac Cancer 2022; 13: 2248-2252.
Desai A, Potter A, Orme J, Leventakos K. Real-world experience of lurbinectedin beyond the second line in small cell lung cancer (P13). IASLC 2022 Targeted Therapies of Lung Cancer Meeting. Available from URL: https://ttlc2022iaslcorg/wp-content/uploads/2022/02/TTLC2022_AbstractBook_Finalpdf.
Estrin A, Wang X, Boccuti A, Prince P, Gautam N, Rengarajan B et al. Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin (1539P). Ann Oncol 2022; 33: S701-S712.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020; 150: 90-96.
Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis. Cancer Treat Rev 2017; 59: 117-122.
Olmedo ME, Forster M, Moreno V, López-Criado MP, Braña I, Flynn M et al. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs 2021; 39: 1275-1283.
Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol 2017; 28: 2559-2566.
Calvo E, Sessa C, Harada G, de Miguel M, Kahatt C, Luepke-Estefan XE et al. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors. Invest New Drugs 2022; 40: 1263-1273.
Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Daurès JP et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005; 93: 1098-1105.